Comorbidities and the use of comedications among patients with chronic hepatitis C in Korea: A nationwide cross-sectional study

• Published in: The Korean journal of internal medicine Vol. 38; no. 3; pp. 338 - 348
• Main Authors: Kwon, Kyung Min, Shim, Jae-Jun, Kim, Gi-Ae, Kim, Bo Ok, Han, Helin, Ahn, Hyun Jung
• Format: Journal Article
• Language: English
• Published: Korea (South) Korean Association of Internal Medicine 01.05.2023; The Korean Association of Internal Medicine; 대한내과학회
• Subjects: Aged; antiviral agents; Antiviral Agents - adverse effects; Comorbidity; Cross-Sectional Studies; drug interactions; Drug Therapy, Combination; Female; Hepacivirus; hepatitis c; Hepatitis C, Chronic - diagnosis; Hepatitis C, Chronic - drug therapy; Hepatitis C, Chronic - epidemiology; Humans; Male; Middle Aged; Original; polypharmacy; Republic of Korea - epidemiology; Sofosbuvir - therapeutic use; therapeutic use; 내과학; Republic of Korea; Polypharmacy; Hepatitis C; Comorbidity; Antiviral agents/therapeutic use; Drug interactions
• ISSN: 1226-3303; 2005-6648
• DOI: 10.3904/kjim.2022.215

Chronic hepatitis C (CHC) is the second leading cause of liver-related mortality and is more prevalent in the elderly population in Korea. Decisions to initiate treatment and selection of proper antiviral agents may be challenging among elderly patients due to relevant comorbidities, comedications, and drug-drug interaction (DDI). It may be helpful to understand the current demographic status and comorbidities of CHC patients in the country. Patients aged ≥ 18 years and diagnosed with CHC (KCD-7 code B18.2) were extracted from the Korean Health Insurance Review & Assessment Service database in 2018. Data on comorbidities and comedications were assessed and potential DDIs were analyzed. A total of 50,476 patients with CHC, with a mean age of 60.3 years and 46.7% male patients were identified. The proportion of patients with cirrhosis, hepatocellular carcinoma, and liver transplantation was 6.0%, 4.1%, and 0.3%, respectively and 37.2% of patients were more than 65 years of age. The three most common comorbidities were diseases of the digestive system (83.7%), respiratory system (58.2%), and musculoskeletal system and connective tissue (57.6%). The three most common comedications were analgesics (91.6%), gastrointestinal agents (85%), and antibacterials (80.3%). Lipid-lowering agents and anticonvulsants were prescribed in 28.5% and 14.8% of patients. Rate of potential DDI for contraindication was 2.2%, 13.1%, and 15.6% with sofosbuvir/velpatasvir, ledipasvir/sofosbuvir, and glecaprevir/pibrentasvir. With the increasing age of patients with CHC, comorbidity, comedication, and potential DDI should be considered when choosing antivirals in Korea. Sofosbuvir-based regimens showed favorable DDI profiles among Korean patients.